Dosing9 min readUpdated 2026-04-10

    Wegovy Dosing Chart: Week-by-Week Dose Escalation Guide

    See the Wegovy dosing chart, including the starting dose, dose-escalation schedule, maintenance dosing, and missed-dose basics.

    Written by Trimi Medical Team. Medically reviewed by Dr. Asad Niazi, MD, MPH. This article covers the Wegovy dosing chart including the starting dose, dose-escalation schedule, maintenance dosing, and missed-dose guidance.

    Quick links: Semaglutide treatment, side effects timeline, and 3-month results.

    Standard Wegovy Dose Ladder

    Wegovy Weekly Dose Progression

    Weeks 1-4: 0.25 mg once weekly. Weeks 5-8: 0.5 mg once weekly. Weeks 9-12: 1 mg once weekly. Weeks 13-16: 1.7 mg once weekly. Maintenance: 1.7 mg or 2.4 mg once weekly depending on tolerance and treatment plan.

    Why Wegovy Starts Low

    Semaglutide commonly causes gastrointestinal symptoms especially early in treatment. Starting at a low dose helps patients adjust before moving higher. That is why the dosing chart is really a side-effect management strategy as much as it is a dose schedule.

    Why the Chart Should Not Feel Like a Race

    Start low at 0.25 mg to allow the body to adjust

    Increase stepwise through the defined dose levels

    Slow down if side effects become difficult at any level

    Use clinician guidance if you are struggling with tolerability

    For a detailed look at what semaglutide side effects look like over time, see our week-by-week guide.

    Maintenance Dosing Is Individualized

    Not every reader ends up at the same maintenance dose. Some will remain at 1.7 mg while others move to 2.4 mg. The right dose depends on tolerability, appetite effects, treatment response, and clinician judgment. See semaglutide results after 3 months for expected outcomes at different stages.

    Missed Dose Basics

    If you miss a Wegovy dose, follow the prescribing information and your clinician's guidance. Timing affects what you should do next. Maintaining a consistent weekly injection schedule helps optimize treatment outcomes. For cost planning, see our Wegovy cost guide and what happens when you stop semaglutide.

    Frequently Asked Questions

    What is the starting dose for Wegovy?

    Wegovy is started at 0.25 mg once weekly for the first 4 weeks. This intentionally low starting dose helps the body adjust to semaglutide and minimizes the likelihood of severe gastrointestinal side effects during the initial treatment period.

    What does the Wegovy dose escalation schedule look like?

    The standard weekly progression is: weeks 1 to 4 at 0.25 mg, weeks 5 to 8 at 0.5 mg, weeks 9 to 12 at 1 mg, weeks 13 to 16 at 1.7 mg, and then maintenance at 1.7 mg or 2.4 mg once weekly depending on tolerance and treatment plan.

    Why does Wegovy start at such a low dose?

    Semaglutide commonly causes gastrointestinal symptoms especially early in treatment. Starting at a low dose helps patients adjust before moving higher. The dosing chart is really a side-effect management strategy as much as it is a dose schedule.

    Does everyone on Wegovy need to reach 2.4 mg?

    No. Not every reader ends up at the same maintenance dose. Some will remain at 1.7 mg while others move to 2.4 mg. The right maintenance dose depends on tolerability, appetite effects, treatment response, and clinician judgment.

    What should I do if I miss a Wegovy dose?

    Official prescribing information matters for missed doses, and timing affects what you should do next. Do not double up on doses without understanding the official instructions. Contact your healthcare provider if you are unsure about what to do after a missed dose.

    Can I slow down the Wegovy dose escalation?

    Yes. The dosing chart should not feel like a race. If side effects are difficult at a given dose level, your clinician may recommend staying at that dose longer or adjusting the plan. Slowing down escalation is a common and appropriate approach to improve tolerability.

    How does Wegovy dosing compare to Ozempic dosing?

    Both Wegovy and Ozempic use semaglutide, but they have different dose ranges and different approved uses. Wegovy's escalation is specifically designed for weight management. For Ozempic-specific dosing information, see our Ozempic dosing chart guide.

    Sources & References

    1. Wegovy prescribing information. FDA.
    2. Wegovy patient information.

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, adjusting, or discontinuing any medication. Individual results vary. Dose adjustments should only be made under medical supervision. Wegovy requires a prescription.

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 10, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    Can Weight Loss Start After the Second Dose. Read the full clinician-reviewed Trimi guide — practical guidance plus Trimi's $99/mo compounded GLP-1 alternative for context.

    Start your GLP-1 journey — from $99/mo

    Get Started